GET THE APP

Rapid, reliable, high sensitivity nucleic acid detection technologies, products and services for cancer diagnosis and therapy monitoring
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Rapid, reliable, high sensitivity nucleic acid detection technologies, products and services for cancer diagnosis and therapy monitoring


Joint Event on 2nd International Conference on Cancer Biology, Therapeutics and Drug Discovery and Delivery & 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics

October 03-04, 2018 | Los Angeles, USA

Michael J Powell

PhD. C.Chem, MRSC, DiaCarta Inc., USA

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

There is a demand for advanced technologies for the detection of circulating cell-free nucleic acids that can be implemented effectively and universally in the modern translational biology research laboratories and hospital pathology laboratories and clinical testing facilities worldwide. Especially as this relates to cancer detection, cancer therapy, and immunotherapy. This workshop will highlight the most recent developments in this field and how DiaCarta, Inc.'s proprietary technologies, products, and services can provide such a solution for the global monitoring of human disease diagnosis, progression, and therapy.

Biography :

Michael J Powell is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, and business and corporate development. He has extensive knowledge and experience in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms. He has published many research papers in leading scientific journals and holds more than 40 patents and patent-pending applications. He received his PhD in medicinal organic chemistry from Loughborough University, Loughborough, UK and also pursued postdoctoral research and a teaching fellowship from the University of Nottingham, Nottingham, UK. He was also a postdoctoral industrial research fellow at the University of Oxford, UK and was instrumental in developing the amperometric glucose sensing technology that was the basis of Medisense, Inc. which was acquired by Abbott Labs for $950M.

E-mail: mpowell@diacarta.com

 

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward